[ser140]-plp tfa

[SER140]-PLP(139-151) (TFA) is a polypeptide fragment of the myelin lipid protein.

N-Formyl-Met-Ala-Ser TFA is a peptide, binds to formyl peptide receptors on neutrophils.N-Formyl-Met-Ala-Ser Peptide (fMet-Ala-Ser) binds to formyl peptide receptors on neutrophils. N-Formylmethionine-containing peptides including the most potent and know

[SER140]-PLP(139-151) acetate is a peptide fragment from myelin proteolipid protein (PLP).

Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function.

[SER140]-PLP(139-151) is a polypeptide fragment of the lipid protein of myelin.

Gly-Arg-Gly-Asp-Ser (GRGDS) is a cell binding protein domain derived from the cell-binding region of fibronectin. Osteopontin uses this motif for cell adhesion.

Arg-gly-glu -Ser(TFA) is a RGD related polypeptide that controls the inhibition of fibrinogen binding to activated platelets by RGDS.

[Leu144,Arg147]-PLP (139-151) is a mutated fragment of the myelin proteolipid protein (PLP), featuring substitutions of tryptophan to leucine and histidine to arginine at positions 144 and 147, respectively. Immunizing mice with this peptide (50 µg) mixed in complete Freund’s adjuvant (CFA) elevates IL-4 levels in the spleen. While it suppresses Th1 cell activation in vitro, it does not do so in vivo; instead, it promotes the development of regulatory T cells. Preimmunization with [Leu144, Arg147]-PLP (139-151) postpones the onset of experimental autoimmune encephalomyelitis (EAE) triggered by encephalitogenic peptides from PLP (178-191), myelin oligodendrocyte glycoprotein (MOG) (92-106), or myelin basic protein (MBP) in mice.

Arg-Gly-Asp-Ser (TFA) is an integrin-binding sequence that serves to inhibit integrin receptor function by directly and specifically binding to pro-caspase-8, pro-caspase-9, and pro-caspase-3, without interacting with pro-caspase-1 [1].

N-Acetyl-Ser-Asp-Lys-Pro (TFA) is an endogenous tetrapeptide that is naturally produced in the bone marrow. It serves as a specific substrate for the N-terminal site of ACE, the enzyme responsible for angiotensin converting activity.

Arg-Gly-Glu-Ser TFA, an RGD-related peptide, serves as a control for evaluating the inhibitory activity of RGDS on fibrinogen binding to activated platelets.